Ed Arce
Stock Analyst at WestPark Capital
(3.16)
# 181
Out of 5,182 analysts
363
Total ratings
47.73%
Success rate
11.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $24 → $28 | $14.01 | +99.86% | 13 | Sep 30, 2025 | |
| TVTX Travere Therapeutics | Assumes: Buy | $30 | $40.77 | -26.42% | 21 | Jun 11, 2025 | |
| MTVA MetaVia | Reiterates: Buy | $132 | $1.40 | +9,328.57% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $75 | $7.02 | +968.38% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $8.85 | +577.97% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $1.41 | +433.81% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $5.67 | +129.28% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $2.45 | - | 17 | Apr 2, 2025 | |
| TLPH Talphera | Reiterates: Buy | $6 | $0.80 | +647.57% | 6 | Apr 1, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $6.68 | +947.90% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $29.24 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $240 | $2.38 | +9,984.03% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.33 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $6.47 | +394.59% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $97.95 | -26.49% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $532.02 | -23.88% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $6.45 | -14.73% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $24.81 | +282.91% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $4.72 | +5.93% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $34.68 | +38.41% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $52.65 | -85.75% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $16.05 | -19.00% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $42.30 | -40.90% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.76 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $25.15 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $35.20 | -80.11% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $34.41 | -38.97% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.74 | - | 2 | Feb 15, 2017 |
Enanta Pharmaceuticals
Sep 30, 2025
Maintains: Buy
Price Target: $24 → $28
Current: $14.01
Upside: +99.86%
Travere Therapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $30
Current: $40.77
Upside: -26.42%
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $132
Current: $1.40
Upside: +9,328.57%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $75
Current: $7.02
Upside: +968.38%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $8.85
Upside: +577.97%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $1.41
Upside: +433.81%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $5.67
Upside: +129.28%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $2.45
Upside: -
Talphera
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.80
Upside: +647.57%
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $6.68
Upside: +947.90%
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $29.24
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $240
Current: $2.38
Upside: +9,984.03%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.33
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $6.47
Upside: +394.59%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $97.95
Upside: -26.49%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $532.02
Upside: -23.88%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $6.45
Upside: -14.73%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $24.81
Upside: +282.91%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $4.72
Upside: +5.93%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $34.68
Upside: +38.41%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $52.65
Upside: -85.75%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $16.05
Upside: -19.00%
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $42.30
Upside: -40.90%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.76
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $25.15
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $35.20
Upside: -80.11%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $34.41
Upside: -38.97%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $5.74
Upside: -